Kezar Life Sciences, Inc.
KZR
$4.50
$0.102.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -83.74M | -95.78M | -98.57M | -101.33M | -101.87M |
| Total Depreciation and Amortization | 1.04M | 1.06M | 1.08M | 1.07M | 1.07M |
| Total Amortization of Deferred Charges | 259.00K | 252.00K | 246.00K | 240.00K | 235.00K |
| Total Other Non-Cash Items | 9.53M | 11.72M | 14.63M | 13.59M | 14.22M |
| Change in Net Operating Assets | -1.30M | 6.38M | 3.53M | 2.79M | 4.71M |
| Cash from Operations | -74.21M | -76.37M | -79.08M | -83.65M | -81.65M |
| Capital Expenditure | -29.00K | -19.00K | -137.00K | -1.51M | -1.81M |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 5.00K | 5.00K | 5.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 80.46M | 84.58M | 79.21M | 81.57M | 77.85M |
| Cash from Investing | 80.43M | 84.56M | 79.08M | 80.06M | 76.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 103.00K | 115.00K | 158.00K | 484.00K | 638.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 103.00K | 115.00K | 158.00K | 484.00K | 638.00K |
| Foreign Exchange rate Adjustments | -63.00K | 50.00K | 11.00K | 3.00K | -2.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.26M | 8.36M | 167.00K | -3.10M | -4.96M |